Register for our EIS fund today

The o2h therapeutics fund

An early stage EIS and/or SEIS investment fund backing biotech therapeutic and related AI opportunities with plug-in capabilities in Cambridge, UK/India and a bridge to the USA.

Minimum investment:


A passion for

EIS investing

Large pharmaceutical companies have been closing down research centres globally for the last decade. This shift in focus of the large pharmaceutical companies has moved them from developing innovation in-house to acquiring innovation externally, forcing us prices for the best science and providing earlier exit opportunities. The team at o2h have access to the most exciting scientific ideas in the through its live working relationships fostered over many years working as a discovery services company giving it far earlier access than competitors to the most promising companies. Early stage companies often need more than just money, o2h Ventures has built a unique integrated model for early stage companies which includes the possibility of offering company’s incubation in its O2h SciTech Park, in Cambridge, UK, and/or the option to jump-start their research activity from o2h Discovery in Ahmedabad, India. The fund is structures to be (S)EIS compliant proving generous income, Inheritance and capital gains tax for UK tax payers.

Our team

Cengiz Tarhan

Cengiz set up FreeMedic PLC in 1993 which he grew over 25 years and is now known as UCL Business PLC, one of the most proli c and successful technology groups in the UK serving UCL and its associated partner hospitals. Over those years Cengiz was directly involved in many licenses and spinouts including PolyMASC Pharmaceuticals PLC, one of the rst university spin-outs to oat on the London AIM in 1995, Medic to Medic Ltd which was sold to Informa PLC in 2005 and Stanmore Implants Worldwide Limited which was acquired by Abingworth and MDY Healthcare in February 2008. More recently UCLB has been at the vanguard of creating the most promising cancer and gene therapy biotechs in the UK including three

Connect on Linkedin

Our EIS investments

(made personally by the Fund Managers)


Exonate is a biopharmaceutical company focussed on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need.


From initial concept to the delivery of candidate drugs – we’re a drug discovery company specialising in cutting-edge cancer treatment.


PhoreMost® has developed a next-generation phenotypic screening platform called ‘SITESEEKER®’ to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.


Talisman Therapeutics, a spinout from the University of Cambridge, is a stem cell research and development company committed to revolutionising the discovery of treatments for Alzheimer’s disease.


Science-led ambitious start up focused on the development of antibacterial compounds with novel mechanisms of action against drug resistant organisms.

Acacia Pharma

Acacia Pharma is a specialty pharmaceutical company focused on the development and commercialisation of new treatments for supportive care of patients with debilitating conditions arising as a consequence of surgery, cancer or cancer treatment.


IOTA Pharmaceuticals has been established to bring you the tools and technologies for Fragment-based Drug Discovery(FBDD) and High-content Screening(HCS).

5 Alarm Bio

5 Alarm Bio is a company dedicated for designing anti-ageing therapies.

Small Pharma

Small Pharma is forging a new path in pharmaceutical development by bridging the gap between academia and industry.

Oxford Drug Design

Oxford Drug Design (formerly InhibOx) is a biotechnology company focused on internal drug discovery. The lead antibacterial programme has identified compounds with the potential to be developed into therapies for Gram-negative bacterial infections, including against strains resistant to multiple current antibacterial drug classes.


A UK-based leading formulation technology company delivering superior biopharmaceuticals via the innovative reformulation of proteins and peptides.


The Repositive platform enables researchers to browse through multiple repositories for the human genomic data they need to power their research.


Privitar facilitates broader use of data while adopting an uncompromising approach to protecting confidential information.

Heartfelt Technologies

Heartfelt Technologies exists to help patients, their families, carers and doctors, to reduce hospital re-admission rates from congestive heart failure de-compensation.


Stemnovate at Cambridge, UK are developing a ‘liver on a chip’ system supported by a $1m Innovate UK award. The platform is based on cutting edge stem cell and micro engineering platform technologies at University of Edinburgh and Cambridge University.

Metrion Biosciences

Metrion Biosciences is a UK-based Contract Research Organization (CRO) focussed on delivering a range of high quality ion channel drug discovery services.

Ventures news

18 Oct 2018

“Investment will accelerate the delivery of significantly improved therapeutic treatments and quality of life for people living with diabetes” Cambridge, UK., 10 September 2018: Arecor Ltd (“the Company”), the UK-based leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, today announces that it has secured £6.0 million of investment from new and existing investors for the clinical development of the Company’s speciality pharma portfolio of proprietary diabetes products. This £6.0 million equity investment into Arecor was led by leading UK institutional investors, Calculus Capital, Downing Ventures, and Albion Capital with significant participation from Arecor’s existing investors. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures. Arecor’s next-generation diabetes product pipeline represents exciting new progress in the field of diabetes that will enable important new treatment regimens and offer greater control of blood glucose to diabetes patients, which is key to improving outcomes and quality of life. This pipeline includes:- @ Proprietary formulations of analogues that are ultra-rapid acting and more closely match a healthy body’s physiological response to blood glucose, leading to better blood glucose (sugar) control – currently a significant challenge @ Highly concentrated rapid acting optimised for the next generation of body-worn miniaturised delivery devices, including the artificial pancreas @ Stable aqueous ready to use used in an emergency to treat severe hypoglycaemia and enabling future use in bi-hormonal artificial pancreas systems These programmes will be progressed through development to demonstrate improved product profiles and health outcomes in human clinical trials.  In addition to these clinical programmes, the investment will allow Arecor to progress its pre-clinical pipeline of diabetes combination products, as well as a range of additional superior biotherapeutics addressing critical unmet needs in key disease areas. The management of diabetes is one of the major global health challenges.  Indeed, the International Diabetes Federation (“IDF”) estimates that there are nearly half a billion (425 million) people currently living with diabetes around the world* and the IDF further estimates that if the global direct and indirect healthcare costs from diabetes are included, the economic impact of diabetes exceeds $1trillion**. *  International Diabetes Federation. IDF Diabetes Atlas, 8th edition. International Diabetes Federation, 2017. Available at: ** Bommer C., Heesemann E., Sagalova V., et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol 2017; 5: 423-30. The improved products, therapeutic pathways and personalised control that Arecor’s products can enable, will make a significant contribution to addressing this challenge.   Arecor will be taking its product portfolio into clinical development itself, however, the Company will ultimately look to partner with specialist diabetes companies for late stage clinical studies and global market access. The Company, which was originally based on unique protein chemistry technology and insights spun out from Unilever, has refined and developed these into the ArestatTM formulation technology platform. This platform has been used extensively to improve the solution properties of numerous protein, anti-body, vaccine and peptide formulations both in collaboration with pharmaceutical partners, as well as for Arecor’s own pipeline.  Arecor has established a proven track record in applying this technology platform to deliver superior biopharmaceutical product profiles across a broad range of therapeutic areas. Dr Sarah Howell, Chief Executive Officer at Arecor, commented: “We are delighted to have secured the investment that we need to progress our lead diabetes programmes through the key stages of clinical development.  With diabetes reaching epidemic proportions worldwide and with close to half a billion people living with the condition today, the opportunity of advancing our diabetes products into human clinical trials and their potential to significantly improve the treatment of this debilitating disease, represents a very exciting and ground-breaking proposition”. Alexander Crawford, Investment Director, Calculus Capital, added: Arecor is applying its unique and highly regarded reformulation technology which will help transform the growing diabetes market. As lead investor, we believe this is an exciting new phase from Arecor in the development of their technology and strong growth potential.” Dr Christoph Ruedig, Partner, Albion Capital, said: “We have followed Arecor for some time and are excited by the societal value of its fast onset, short duration action. Its technology is highly differentiated and the Company is leading the sector in the area of stabilising liquid formulations for injectable drugs. We look forward to working with the strong leadership team to bring this extraordinary proposition to fruition and in doing so, aid many diabetic patients across the UK and beyond.” Richard Lewis, Investment Director, Downing Ventures, concluded: “As an investment opportunity, Arecor combines a solid and high margin technology business alongside a proprietary product offering that fulfils major unmet medical need.  As a result, we believe that the diabetes pipeline should successfully attract quality international commercial partners. ” Arecor is one of o2h Ventures’ investment.

25 May 2018

Stemnovate which is advancing 'organ on chip' technology has closed its seed investment round with a team of eight angels led by team of o2h ventures, whose co-founder Sunil Shah is joining the board as chairman.Stemnovate specialises in stem cell research, cellular differentiation and microengineering. Its 'liver on a chip' technology has exciting potential for pre-clinical hepatotoxicity testing, replicating the microarchitecture and functions of the human liver and taking account of variation in patient's individual genetic backgrounds. Mr Shah, who is an MBA from Cambridge University is a serial entrepreneur who co-founded two companies in information technology and life sciences sector O2h ventures involves discovery services and collaboration, seeding drug discovery, academic in-licensing and bio-technology incubation.He said "current models for screening new drugs for liver toxicity are not predictive,there is an urgent need for the reliable screening technology before millions are invested into a clinical trial only to fail due to liver toxicity". For more information- Stemnovate Secure....

17 Apr 2018

In January, Exonate, one of o2h venture's investement, was approached by the British Business Bank to feature in a series of videos to highlight their Business Finance Guide. The British Business Bank and Angel Co Fund have provided valuable funding and support to Exonate and our investment was highlighted an excellent case study to promote the banks work. Sunil Shah, CEO, o2h Ventures and Peter Cowley of Angel Co Fund were invited to take part and spent time being filmed in The Bradfield Centre in the Cambridge Science park. Watch the video here Read the full article


December 25th 2018 09:12:04

o2h Cordially Wishes You A Merry Christmas!


December 14th 2018 01:12:11

RT @chategroup_: World Energy Conservation Day is celebrated on 14th December globally to highlight the importance of energy consumption an…


December 11th 2018 12:12:27

RT @OncologyEvent: Chemists discover an unexpected synergy between two types of cancer drugs!
#health #can…


December 11th 2018 11:12:27

RT @aheblog: Our latest #healtheconomics round-up discusses a leading article in PharmacoEconomics on the inclusion of future costs in cost…


December 11th 2018 08:12:31

RT @JonathanHoltby: Just told my most harrowing Startup Failure story at the Cambridge Startups: Failure event. Broke me at the time - felt…


December 7th 2018 01:12:04

Speaker and Panelist @sunilshah123, CEO at o2h, also part of Cambridge Angels, attending the Failure meetup in Camb…


December 7th 2018 10:12:59

RT @Emmin: Our very own #cambridgeangel Sunil Shah on the panel at The Lab, talking about Cambridge failures #cambridgefailedme https://t.c


December 7th 2018 10:12:54

RT @markamzprospect: Full house at The Lab celebrating failure! My takeaway celebrate successes no matter how small. Fun and informative ev…


December 7th 2018 09:12:08

Speaker and Panelist @sunilshah123 CEO @o2hventures attending the Failure meetup @TheLabCambridge #cambridgefailedme


December 5th 2018 10:12:04

Make no bones about it, research aboard the Space Station has led to the development of new drugs on Earth that com…

o2h culture, people & careers.